Show simple item record

dc.contributor.authorTaprogge, Jen_US
dc.contributor.authorWadsley, Jen_US
dc.contributor.authorMiles, Een_US
dc.contributor.authorFlux, GDen_US
dc.date.accessioned2021-01-18T11:15:15Z
dc.date.issued2021-02en_US
dc.identifier.citationClinical oncology (Royal College of Radiologists (Great Britain)), 2021, 33 (2), pp. 131 - 136en_US
dc.identifier.issn0936-6555en_US
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/4287
dc.identifier.eissn1433-2981en_US
dc.identifier.doi10.1016/j.clon.2020.12.002en_US
dc.description.abstractMulticentre clinical trials involving a dosimetry component are becoming more prevalent in molecular radiotherapy and are essential to generate the evidence to support individualised approaches to treatment planning and to ensure that sufficient patients are recruited to achieve the statistical significance required. Quality assurance programmes should be considered to support the standardisation required to achieve meaningful results. Trials should be designed to ensure that dosimetry results from image acquisition systems across centres are comparable by incorporating steps to standardise the methodologies used for the quantification of images and dosimetry. Furthermore, it is essential to assess the expertise and resources available at each participating site prior to trial commencement. A quality assurance plan should be drawn up and training provided if necessary. Standardisation of quantification and dosimetry methodologies used in a trial are essential to ensure that results from different centres may be collated. In addition, appropriate uncertainty analysis should be carried out to correct for differences in methodologies between centres. Recommendations are provided to support dosimetry studies based on the experience of several previous and ongoing multicentre trials.en_US
dc.formatPrint-Electronicen_US
dc.format.extent131 - 136en_US
dc.languageengen_US
dc.language.isoengen_US
dc.titleRecommendations for Multicentre Clinical Trials Involving Dosimetry for Molecular Radiotherapy.en_US
dc.typeJournal Article
dcterms.dateAccepted2020-12-02en_US
rioxxterms.versionofrecord10.1016/j.clon.2020.12.002en_US
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by/4.0en_US
rioxxterms.licenseref.startdate2021-02en_US
rioxxterms.typeJournal Article/Reviewen_US
dc.relation.isPartOfClinical oncology (Royal College of Radiologists (Great Britain))en_US
pubs.issue2en_US
pubs.notesNo embargoen_US
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Radioisotope Physics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Radioisotope Physics/Radioisotope Physics (hon.)
pubs.publication-statusAccepteden_US
pubs.volume33en_US
pubs.embargo.termsNo embargoen_US
icr.researchteamRadioisotope Physicsen_US
dc.contributor.icrauthorTaprogge, Janen_US
dc.contributor.icrauthorFlux, Glennen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record